One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
On the Nose: Reducing Nasopharyngeal Cancer–Related Mortality Using Risk-Based Epstein-Barr Virus Serology Screening
doi : 10.1200/JCO-24-01605
2025, Volume 43 (1)
How Racialized Approaches to Opioid Use Disorder and Opioid Misuse Management Hamper Pharmacoequity for Cancer Pain
doi : 10.1200/JCO.24.00705
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
doi : 10.1200/JCO.24.00340
Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial
doi : 10.1200/JCO.23.01296
Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors
doi : 10.1200/JCO.23.01779
Effectiveness of a Cardiovascular Health Electronic Health Record Application for Cancer Survivors in Community Oncology Practice: Results From WF-1804CD
doi : 10.1200/JCO.24.00342
Effect on Travel Distance of a Statewide Regionalization Policy for Initial Breast Cancer Surgery
doi : 10.1200/JCO.23.02638
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia
doi : 10.1200/JCO.24.00235
Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
doi : 10.1200/JCO.24.00826
Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
doi : 10.1200/JCO-24-02245
Underrated But Significant Risk Factors of Osteoradionecrosis of the Jaw in Patients With Head and Neck Cancer
doi : 10.1200/JCO.24.01020
Surveillance Systemic Imaging After Curative Intent for Breast Cancer: A Double Standard?
doi : 10.1200/JCO.24.01186
Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
doi : 10.1200/JCO-24-02458
Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
doi : 10.1200/JCO-24-02469
Erratum: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
doi : 10.1200/JCO-24-02470
